Pharmaceutical

STAT+: Pharmalittle: We’re reading about Lilly selling ...

Eli Lilly started an online service offering telehealth prescriptions and direct...

Opinion: I went on a mind-boggling journey to get my so...

One man’s mind-boggling journey to get his son’s necessary ADHD medication cover...

Opinion: The misguided reason why providers aren’t pres...

Providers shouldn’t be afraid of buprenorphine for opioid use disorder making it...

A young dancer, diagnosed with scoliosis, learns to adv...

Caught during a screening at school, a young dancer's diagnosis of scoliosis led...

Pharmaceutical Technology Excellence Awards 2023: KAI C...

KAI, a technology company based in the UK, is a Category Award Winner for Innova...

Rhythm expands obesity portfolio with Phase II weight l...

Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB5...

Boehringer and 3T Biosciences partner to develop cancer...

Boehringer Ingelheim has signed a deal with 3T Biosciences for the discovery and...

Avistone raises $140m to support drug research and deve...

Avistone has closed its Series B financing round, raising 1bn yuan ($140m), to s...

AmyriAD leaves no leaf unturned with upcoming Phase III...

The company aims to drive a small molecule resurgence with its lead Alzheimer’s ...

Signal: UK online pharmacies selling prescription drugs...

A BBC team was able to buy over 1600 prescription pills by supplying fake data, ...

Intellia propels into 2024 with CRISPR pipeline updates

Intellia Therapeutics announced its clinical goals for the next few years, pushi...

Insilico teams up with Menarini for breast cancer KAT6 ...

Menarini subsidiary Stemline will receive upfront and milestone payments, potent...

MOMA Therapeutics and Roche sign cancer drug discovery ...

MOMA Therapeutics and Roche have signed a strategic partnership and licensing ag...

AbbVie and Umoja to develop new CAR-T therapies for cancer

AbbVie and Umoja Biopharma partnered for the development of in-situ CAR-T cell t...

STAT+: Illumina chief commercial officer leaves to lead...

Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and...

At JPM, how much health policy talk should we expect?

How much health policy talk should we expect at #JPM2024?